Deutsche Bank analyst James Shin downgraded Merck (MRK) to Hold from Buy with a price target of $105, down from $128. The firm believes the ...

According to Reuters, the grocery retailer notified Express Scripts in September 2022 of its plan to terminate the pharmacy provider agreement for commercial customers because of an “unsustainable” ...

AbbVie (NYSE:ABBV) continues to navigate the challenges of Humira's loss of exclusivity while leveraging its diverse portfolio and robust pipeline to drive future growth. With a gross profit ...

AbbVie (NYSE:ABBV) continues to navigate the challenges of Humira's loss of exclusivity while leveraging its diverse portfolio and robust pipeline to drive future growth. With a gross profit margin of ...

As the company navigates the post-Humira era, investors and analysts are closely watching its performance and future prospects. According to InvestingPro data, AbbVie stands as a prominent player ...

AbbVie faces its share of headwinds like Humira biosimilar erosion, increasing competitive pressure on cancer drug Imbruvica and slow market growth trends for fillers in the United States and China.

AbbVie has demonstrated resilience in the face of significant challenges, particularly the loss of exclusivity (LOE) for its blockbuster drug Humira. The company's second-quarter 2024 results ...

AbbVie (NYSE:ABBV) will report Q4 2024 results next week and provide guidance for 2025. The company is handling the erosion of Humira quite well, but the trajectory of the decline in Humira's net ...

For most of those years, AbbVie enjoyed lucrative success with Humira. However, the company's revenue has dipped since Humira lost patent exclusivity in 2023, and the stock price has only ...

Pharmaceutical powerhouse AbbVie (NYSE: ABBV) has been a beast since it spun off from Abbott Laboratories in 2012. Over the past decade, the stock has averaged a dividend yield of 3.5% while ...